Drug Search Results
More Filters [+]

Nifurtimox

Alternative Names: nifurtimox, lampit
Latest Update: 2024-06-12
Latest Update Note: Clinical Trial Update

Product Description

Nifurtimox has been used to treat Chagas disease for 40 years, but tolerance and safety data in adults are scarce. Nifurtimox is poorly tolerated among adults with chronic Chagas disease, resulting in a low treatment completion rate. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20932171/)

Mechanisms of Action: DNA Cleaver

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Chile | Colombia | Mexico | Peru | United Kingdom | United States

Approved Indications: Chagas Disease | Trypanosomiasis

Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nifurtimox

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Brain Stem Cancer|Breast Cancer|Central Nervous System Cancer|Glioma|Lung Cancer|Medulloblastoma|Melanoma|Neuroblastoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20190136

P1

Recruiting

Neuroblastoma

None

CTR20220156

P1

Recruiting

Brain Stem Cancer|Glioma|Central Nervous System Cancer|Lung Cancer|Medulloblastoma|Breast Cancer|Melanoma

None

Recent News Events